Gene-Tailored therapy shows promise for advanced lung cancer
NCT ID NCT00883480
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether customizing chemotherapy based on specific gene mutations (EGFR and BRCA1) could improve outcomes for 153 patients with advanced lung adenocarcinoma. Participants received treatments matched to their tumor's genetic profile. The goal was to see if this personalized approach led to better tumor shrinkage and survival.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED LUNG ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hospital Carlos Haya
Málaga, Málaga, Spain
-
Ico-Hospital Universitarios Germans Trias I Pujol
Badalona, Barcelona, 08916, Spain
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new immunotherapy combo outsmart advanced lung cancer?
- Double attack on mutant KRAS: can two targeted drugs outsmart resistant cancers?
- Seeing the fight: new imaging tracer may reveal how immune cells attack lung cancer
- Could a bronchial wash detect lung cancer mutations faster?
- Can a targeted pill outsmart a tough lung cancer mutation?
- Can a PET scan reveal hidden heart harm from lung cancer treatment?